Telix Shares Rise After FDA Accepts Resubmitted NDA for TLX101-Px
Telix Pharmaceuticals ADRs climbed after the U.S. Food and Drug Administration accepted the company’s resubmitted New Drug Application for TLX101-Px, also called Pixclara or Floretyrosine F 18. The FDA set a PDUFA goal date of September 11, 2026. The agent is intended to help differentiate recurrent or progressive glioma from treatment-related chan…